Effects of Cardiovascular Risk Factors on Cardiac STAT3

• Published in: International journal of molecular sciences 2018-11, Vol.19 (11), p.3572
• Main Authors: Pipicz, Márton, Demján, Virág, Sárközy, Márta, Csont, Tamás
• Format: Article
• Language: English
• Subjects: Aging; Amino acids; Animals; Binding sites; Cardiac conditioning; Cardiac muscle; Cardiomyocytes; cardioprotection; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - metabolism; Cell differentiation; comorbidity; Congestive heart failure; Coronary artery disease; Diabetes; Diabetes mellitus; Doxorubicin; Extracellular matrix; Fibroblasts; Gene expression; Glucose; Heart; Homeostasis; Humans; Ischemia; JAK; Kinases; Ligands; Membrane permeability; Mitochondria; Mitochondrial DNA; Mitochondrial permeability transition pore; mPTP; Muscles; myocardial infarction; Myocardium - metabolism; Myocardium - pathology; Obesity; Phosphorylation; Preconditioning; Reperfusion; Review; Risk analysis; Risk Factors; Signal processing; Signal Transduction; STAT family; Stat3 protein; STAT3 Transcription Factor - chemistry; STAT3 Transcription Factor - metabolism; Transcription
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms19113572

Nuclear, mitochondrial and cytoplasmic signal transducer and activator of transcription 3 (STAT3) regulates many cellular processes, e.g., the transcription or opening of mitochondrial permeability transition pore, and its activity depends on the phosphorylation of Tyr705 and/or Ser727 sites. In the heterogeneous network of cardiac cells, STAT3 promotes cardiac muscle differentiation, vascular element formation and extracellular matrix homeostasis. Overwhelming evidence suggests that STAT3 is beneficial for the heart, plays a role in the prevention of age-related and postpartum heart failure, protects the heart against cardiotoxic doxorubicin or ischaemia/reperfusion injury, and is involved in many cardioprotective strategies (e.g., ischaemic preconditioning, perconditioning, postconditioning, remote or pharmacological conditioning). Ischaemic heart disease is still the leading cause of death worldwide, and many cardiovascular risk factors contribute to the development of the disease. This review focuses on the effects of various cardiovascular risk factors (diabetes, aging, obesity, smoking, alcohol, depression, gender, comedications) on cardiac STAT3 under non-ischaemic baseline conditions, and in settings of ischaemia/reperfusion injury with or without cardioprotective strategies.